Imualfa 1.6mg Injection

• Control hepatitis B virus (HBV)

Patients experience acute and severe side effects when using Imualfa 1.6mg Injection, as with any other medication. Consult the healthcare professional if any of the symptoms persist or worsen:

• Fever
• Muscle ache
• Tiredness
• Nausea
• Vomiting

• Joint pain

• Decreased muscle tone

• Skin rash

• Injection site reactions (pain, swelling or redness)

Imualfa 1.6mg Injection should be correctly administered by a healthcare professional. The injection should be taken on the upper arms, buttocks, and abdomen, given by a nurse or doctor in a hospital or clinic. Never consume an overdose on the missed one as this may increase the risk of side effects.

Imualfa 1.6mg Injection boosts the immune system by increasing the activity of immune cells that have protective functions, helping the body better control the HBV virus. This medicine also works in reducing the amount of virus in AIDS. It also prevents the HBV virus from multiplying in the body. It helps control infections and makes the immune system work better. This lowers the chances of getting complications and improves the quality of life.

• Ancell, C. D., Phipps, J., & Young, L. (2001). Thymosin alpha-1. American journal of health-system pharmacy, 58(10), 879-885. https://pubmed.ncbi.nlm.nih.gov/11381492/
• Pei, F., Guan, X., & Wu, J. (2018). Thymosin alpha 1 treatment for patients with sepsis. Expert opinion on biological therapy, 18(sup1), 71-76. https://pubmed.ncbi.nlm.nih.gov/30063866/
• Dinetz, E., & Lee, E. (2024). Comprehensive review of the safety and efficacy of Thymosin alpha 1 in human clinical trials. Alternative Therapies in Health and Medicine, 30(1), 6-12. https://pubmed.ncbi.nlm.nih.gov/38308608/
  
• Dominari, A., Hathaway III, D., Pandav, K., Matos, W., Biswas, S., Reddy, G., ... & Baralt, D. (2020). Thymosin alpha 1: a comprehensive review of the literature. World journal of virology, 9(5), 67. https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/
• Liu, F., Wang, H. M., Wang, T., Zhang, Y. M., & Zhu, X. (2016). The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC infectious diseases, 16(1), 488. https://pubmed.ncbi.nlm.nih.gov/27633969/